Lyka Labs Limited

Corporate Office : Ground Floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036.
Phone : 022 6611 2200 / 244 /290 • Website : www.lykalabs.com • Email : enquiry@lykalabs.com

LYKA
Healthcare through Innovation

10th August, 2026

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001	National Stock Exchange of India Limited Exchange Plaza, G. Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051
Script Code: 500259	Script Code: LYKALABS

Dear Sir/Madam,

Sub: Outcome of the Board Meeting – 10th August, 2026
Ref: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the SEBI Listing Regulations)

With reference to the above captioned subject and pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company in their meeting held today i.e. 10th August, 2026, has *inter-alia*, considered, approved and taken on record the following:

1. **Unaudited Financial Results for the first quarter ended 30th June, 2026**

Unaudited Financial Results (Standalone & Consolidated) for the first quarter ended 30th June, 2026 alongwith Limited Review Report thereon is enclosed herewith as **Annexure -1**.

2. **Consider and approve disinvestment of shares from Lyka BDR International Limited**

With reference to the above and in compliance with Regulation 30 of SEBI LODR, we hereby inform you that the Board of Directors of the Company at its meeting held on 10th August, 2026, inter alia, has considered and approved the proposal for divestment of 100% Equity stake/investment held in its subsidiary company viz. Lyka BDR International Limited. Further, requisite authority has been delegated to Audit committee of the Company to take necessary steps in this regard.

Lyka BDR International Limited is not a material subsidiary of the Company.

The disclosure required under Regulation 30 of the SEBI LODR read with Disclosure Circular, are enclosed herewith as **Annexure - 2**.

The above information will also be available on the website of the Company at www.lykalabs.com.
The meeting of the Board of Directors commenced at 11.00 A.M. and concluded at 12.20 PM.

Kindly take the same on your record.

Thanking you,

Yours faithfully,
For **Lyka Labs Limited**

SHAILENDRA KUMAR AGRAWAL
Digitally signed by SHAILENDRA KUMAR AGRAWAL
Date: 2026.08.10 12:22:32 +05'30'

Shailendra Agrawal
Company Secretary and Compliance Officer
Encl.: as above

INDIA

D. KOTHARY & CO.
Chartered Accountants

Independent Auditor's Review Report on the Unaudited Standalone Financial Results for the quarter ended June 30, 2026 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Lyka Labs Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Lyka Labs Limited** ("the Company") for the quarter ended June 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W

Mehul .N Patel
(Partner)
Membership No. 132650

D. KOTHARY & CO. MUMBAI CHARTERED ACCOUNTANTS

UDIN: 26132650GXTSWH4353

Place: Mumbai
Date: August 10, 2026

102- Ameya House, Next to Azad Nagar Metro Station, Above Standard Chartered Bank, Andheri (W), Mumbai - 400 058.
Tel (B): +91 22 6865 1155 / 1166 / 1111 • E-mail: info@dkothary.com • Website : www.dkothary.com

Lyka Labs Limited

Corporate Office : Ground floor, Spencer Building, 30, Forjett Street, Grant Road (West), Mumbai - 400 036
• Phone : 6611 2200/290 Website : www.lykalabs.com • Email : enquiry@lykalabs.com

LYKA
Healthcare Through Innovation

Statement of Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2026

(₹ in lakhs)

	Particulars	Quarter Ended			Year Ended
		30th Jun, 2026	31st Mar, 2026	30th Jun, 2025	31st Mar, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	**Revenue**				
	Revenue from Operations	4230.94	2803.07	2917.64	12090.53
	Other Income	41.85	50.98	77.34	397.44
II	**Total Income**	**4272.79**	**2854.04**	**2994.98**	**12487.96**
III	**Expenses**				
(a)	Cost of Materials Consumed	1120.41	742.58	804.94	3177.43
(b)	Purchase of Stock in trade	750.15	499.88	224.86	1479.99
(c)	Change in inventories of Finished Goods, work-in-progress and stock-in-trade	(225.72)	(139.66)	15.97	(107.94)
(d)	Employee benefits expense	1147.61	1287.29	898.24	4160.22
(e)	Finance Costs	100.82	87.33	85.14	332.67
(f)	Depreciation and amortisation expense	200.96	204.39	211.18	845.98
(g)	Other expenses	979.21	861.23	637.91	3621.71
	Total Expenses	**4073.44**	**3543.04**	**2878.24**	**13510.05**
IV	**Profit / (Loss) before Exceptional Items and Taxes (II - III)**	**199.35**	**(688.99)**	**116.74**	**(1022.09)**
V	**Exceptional Items (Net)**	-	2301.44	-	2301.44
VI	**Profit / (Loss) before Tax**	**199.35**	**(2990.43)**	**116.74**	**(3323.53)**
VII	**Tax Expenses**				
	Current Tax	-	(49.00)	31.00	-
	Earlier Year Tax	-	82.79	-	82.79
	Deferred Tax	(10.68)	(47.01)	4.67	(177.48)
VIII	**Net Profit / (Loss) after Tax**	**210.03**	**(2977.21)**	**81.07**	**(3228.84)**
IX	**Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)**	-	(12.56)	-	(14.40)
X	**Total Comprehensive Income / (Loss)**	**210.03**	**(2989.77)**	**81.07**	**(3243.25)**
	Paid up Equity Share Capital (FV ₹ 10/- each)	3615.27	3615.27	3615.27	3615.27
	Other Equity				5084.64
XI	**Basic and diluted earnings per share (Not annualised for the quarters)**	0.58	(8.24)	0.22	(8.93)

Notes:

1 The above Unaudited standalone financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 10th August 2026.

2 The Hon'ble National Company Law Tribunal ('NCLT'), Ahmedabad Bench, has sanctioned the Scheme of Amalgamation for the merger of Lyka Export Limited (the Transferor Company), with the Lyka Labs Limited (the Transferee Company), under Sections 230 to 232 of the Companies Act, 2013, vide its Order dated 16th March 2026.
The accounting treatment pursuant to the scheme has been given effect to from the date required under IND AS 103 – Business Combinations.Accordingly, the figures has been restated for respective periods.

3 The Statutory Auditors have expressed an unqualified Conculsion on the Unaudited Standalone financials results for the quarter ended 30th June 2026.

4 The Company operates in one business segment i.e. "Pharmaceuticals".

5 The figures for the previous year have been restated / rearranged wherever considered necessary.

LYKA LABS LIMITED MUMBAI

For Lyka Labs Limited

Kunal Gandhi
Managing Director & CEO
DIN: 01516156

Mumbai : 10th August, 2026

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2026, pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Lyka Labs Limited

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **Lyka Labs Limited** ("the Parent"), which includes its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2026 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

   Parent Company:
   - Lyka Labs Limited

   Subsidiary
   - Lyka BDR International Limited

5. The accompanying unaudited consolidated financial result includes unaudited interim financial results and other unaudited financial information in respect of one subsidiary, whose interim financial results reflect total revenues of Rs. Nil, total net profit/(loss) after tax of Rs. (5.36) lakhs, total comprehensive income of Rs. (5.36) lakhs for the quarter ended June 30, 2026, as considered in the Statement which have been reviewed by us. Our conclusion is not modified in respect of this matter

D. KOTHARY & CO. MUMBAI CHARTERED ACCOUNTANTS

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W

D. KOTHARY & CO. MUMBAI CHARTERED ACCOUNTANTS

Mehul .N Patel
(Partner)
Membership No. 132650

UDIN: 26132650VSKHDV6853.

Place: Mumbai
Date: August 10, 2026

Statement of Consolidated Unaudited Financial Results for the Quarter Ended 30th June, 2026

(₹ in lakhs)

PARTICULARS		Quarter Ended			Year Ended
		30th Jun, 2026	31st Mar, 2026	30th Jun, 2025	31st Mar, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	**Revenue**				
	Revenue from Operations	4,230.94	2,803.07	3,302.54	12,844.46
	Other Income	41.85	61.12	63.09	349.78
II	**Total Income**	**4,272.79**	**2,864.19**	**3,365.63**	**13,194.24**
III	**Expenses**				
(a)	Cost of Materials Consumed	1,120.41	742.58	804.94	3,177.43
(b)	Purchase of Stock in trade	750.15	499.88	453.00	1,950.40
(c)	Change in inventories of finished goods, work-in-progress and stock-in-trade	(225.72)	(139.49)	15.89	(107.94)
(d)	Employee benefits expense	1,149.02	1,291.28	904.84	4,184.89
(e)	Finance Costs	100.81	70.15	85.38	316.04
(f)	Depreciation and amortisation expense	200.96	204.39	211.18	845.98
(g)	Other expenses	982.36	1,054.02	755.23	4,005.38
	Total Expenses	**4,077.99**	**3,722.81**	**3,230.46**	**14,372.18**
IV	**Profit / (Loss) before Exceptional Items and Taxes (II -**	**194.80**	**(858.62)**	**135.17**	**(1,177.94)**
V	**Exceptional Items (Net)**	-	-	-	-
VI	**Profit / (Loss) before Tax**	**194.80**	**(858.62)**	**135.17**	**(1,177.94)**
VII	**Tax Expenses**				
	Current Tax	-	(49.00)	31.00	-
	Earlier Year Tax	-	82.79	-	82.79
	Deferred Tax	(9.86)	(85.78)	4.55	(217.17)
VIII	**Net Profit / (Loss) after Tax**	**204.66**	**(806.63)**	**99.62**	**(1,043.56)**
IX	**Other Comprehensive Income**	-	(12.55)	-	(14.40)
X	**Total Comprehensive Income / (Loss)**	**204.66**	**(819.18)**	**99.62**	**(1,057.97)**
XI	**Profit After Tax Attributed to**				
	Owners of the Parent	206.52	(760.68)	93.17	(1,003.18)
	Non-controlling Interest	(1.86)	(45.96)	6.45	(40.40)
		204.66	**(806.64)**	**99.62**	**(1,043.58)**
XII	**Other Comprehensive Income**				
	Owners of the Parent	-	(12.55)	-	(14.40)
	Non-controlling Interest	-	-	-	-
		-	**(12.55)**	**-**	**(14.40)**
XIII	**Total Comprehensive Income / (Loss)**				
	Owners of the Parent	206.52	(773.23)	93.17	(1,017.58)
	Non-controlling Interest	(1.86)	(45.96)	6.45	(40.40)
		204.66	**(819.19)**	**99.62**	**(1,057.98)**
XIV	Paid up Equity Share Capital (FV Rs.10/- each)	3,615.27	3,615.27	3,615.27	3,615.27
	Other Equity				5,624.07
XV	**Basic and diluted earnings per share**	0.57	(2.10)	0.25	(2.77)

Notes:

1 The above Unaudited Consolidated Financial Results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 10th August 2026.

2 The Hon'ble National Company Law Tribunal ('NCLT'), Ahmedabad Bench, has sanctioned the Scheme of Amalgamation for the merger of Lyka Export Limited (the Transferor Company), with the Lyka Labs Limited (the Transferee Company), under Sections 230 to 232 of the Companies Act, 2013, vide its Order dated 16th March 2026.
The accounting treatment pursuant to the scheme has been given effect to from the date required under IND AS 103 – Business Combinations. Accordingly, the figures has been restated for respective periods.

3 The Statutory Auditors have expressed an unqualified conculsion on the Unaudited Consolidated Financials Results for the quarter ended 30th June 2026.

4 The Company operates in one business segment i.e. "Pharmaceuticals".

5 The figures for the previous year have been restated / rearranged wherever considered necessary.

LYKA LABS LIMITED MUMBAI

For Lyka Labs Limited

Kunal Gandhi
Managing Director & CEO
DIN: 01516156

Mumbai : 10th August, 2026

ANNEXURE - 2

Disclosure for the Sale or disposal of unit(s) or division(s) or subsidiary of the listed entity.

<table>
<tr><th>Items to be disclosed</th><th colspan="3">Details</th></tr>
<tr><td rowspan="4">a) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year i.e. 31st March 2026</td><td colspan="3">Name of the subsidiary: Lyka BDR International Limited</td></tr>
<tr><td>Particulars</td><td>Amount (INR in Lakhs)</td><td>Percentage</td></tr>
<tr><td>Total Income</td><td>1055.48</td><td>8% of consolidated income of the Company</td></tr>
<tr><td>Net worth</td><td>(449.17)</td><td>NA</td></tr>
<tr><td>b) Date on which the agreement for sale has been entered into</td><td colspan="3" rowspan="6">The Board has authorised the Audit Committee to decide, inter alia, the matters relating to (b) to (g).

Details as-per clause (b) to (g) will be intimated to the Stock Exchanges as and when the transaction for sale is finalised /completed in due course.</td></tr>
<tr><td>c) The expected date of completion of sale/disposal</td></tr>
<tr><td>d) Consideration received from such sale/disposal</td></tr>
<tr><td>e) Brief details of buyers</td></tr>
<tr><td>f) Whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;</td></tr>
<tr><td>g) Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"</td></tr>
<tr><td>h) Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale</td><td colspan="3">Not applicable</td></tr>
</table>